J. Usuda, S. Ichinose, T. Ishizumi, H. Hayashi, K. Ohtani, S. Maehara, S. Ono, H. Honda, N. Kajiwara, O. Uchida, H. Tsutsui, T. Ohira, H. Kato and N. Ikeda, “Breast Cancer Resistant Protein (BCRP) is a Molecular Determinant of the Outcome of Photodynamic Therapy (PDT) for Centrally Located Early Lung Cancer,” Lung Cancer, Vol. 67, No. 2, 2010, pp. 198-204. doi:/10.1016/j.lungcan.2009.04.002

has been cited by the following article:

• TITLE: Rapid and Simple Analysis of N-Aspartylchlor in E6 (Talaporfin) Using Fluorescence Microtiterplate and Its Application for Determination in Cells, Tissues and Blood

  AUTHORS: Hiroko Yokoyama, Miyabi Ebara, Fuyuki Nakamura, Aina Nanasawa, Sachiko Tanaka, Kenji Onda, Kentaro Sugiyama, Kazuhiko Kasuya, Gulimire Muhetaer, Motohide Shimazu, Toshihiko Hirano

  KEYWORDS: N-Aspartylchlorin E6 (Talaporfin); Fluorescence Microtiterplate Analysis; Breast Tumor Cells; Tumor-Bearing Mouse; Human Plasma

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.5, October 17, 2012

  ABSTRACT: N-aspartylchlorin e6 (talaporfin) concentrations in cancer cells, mouse liver tissues, and human plasma specimens were determined with fluorescence microtiter plate analysis. Talaporfin standard curves were obtained in each of the sample specimens of cells, mouse tissues, or human plasma including serial concentration of talaporfin. The correlation co-efficiencies (r2) of talaporfin standard curves were 0.99-1.00, and the CV less than 5%. Talaporfin incorporation into cells of human breast cancer cell line MCF-7 after incubating with 25 μg/mL talaporfin for up to 24 h revealed that the t-max of the drug incorporation was approximately 5 h, and the maximum drug concentration incorporated was 25 μg/107 cells. Talaporfin incorporation into MCF-7 cells was significantly decreased in the presence of 3 μg/mL cyc-losporine (p